Table 2.

Correlations of expressions of AKT, mTOR and P70S6K with clinicopathological features of patients with NPC.

Clinicopathological feature	n	Positive expression of AKT (%)	p	Positive expression of mTOR (%)	p	Positive expression of P70S6K (%)	p
Age (year)
<50	181	70.72%	0.356	74.03%	0.889	58.56%	0.533
≥50	104	65.38%		75.00%		62.50%
Gender
Male	184	67.39%	0.593	73.37%	0.671	61.96%	0.379
Female	101	71.29%		76.24%		56.44%
Smoking history
Yes	162	66.05%	0.302	72.22%	0.411	58.02%	0.465
No	123	72.36%		77.24%		62.60%
Alcohol use
Yes	120	70.83%	0.605	75.00%	0.891	60.83%	0.903
No	165	67.27%		73.94%		59.39%
Pathological stages
Keratinizing	94	71.28%	0.587	79.79%	0.152	65.96%	0.159
Non-keratinizing	191	67.54%		71.73%		57.07%
T-staging
T1-T2	101	55.45%	0.001	51.49%	<0.001	35.64%	<0.001
T3-T4	184	76.09%		86.96%		73.37%
N-staging
N0-N1	96	60.42%	0.042	53.13%	<0.001	37.50%	<0.001
N2-N3	189	73.02%		85.19%		71.43%
Distant metastasis
No	79	53.16%	0.001	51.90%	<0.001	39.24%	<0.001
Yes	205	74.63%		83.41%		68.29%
Clinical staging
I/II stage	94	60.64%	0.042	55.32%	<0.001	41.49%	<0.001
III/IV stage	191	72.77%		83.77%		69.11%
Differentiation degree
Low/undifferentiation	218	76.15%	<0.001	83.03%	<0.001	67.89%	<0.001
Medium/high differentiation	67	44.78%		46.27%		34.33%

mTOR, mammalian target of rapamycin; P70S6K, p70 ribosomal S6 kinase; NPC, nasopharyngeal carcinoma.